Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 688 results
Found 688 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

C

Li JZ, Brumme CJ, Lederman MM, et al. "Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial." PLoS ONE. 2012;7(3):e34134.
Bosch RJ, Wang R, Vaida F, Lederman MM, Albrecht MA. "Changes in the slope of the CD4 cell count increase after initiation of potent antiretroviral treatment." J. Acquir. Immune Defic. Syndr.. 2006;43(4):433-5.
Wyatt CM, Kitch D, Gupta SK, et al. "Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine." J. Acquir. Immune Defic. Syndr.. 2014;67(1):36-44.
Kelesidis T, Tran TTien T, Brown TT, et al. "Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s." Antivir. Ther. (Lond.). 2016.
Krishnan S, Schouten JT, Atkinson B, et al. "Changes in metabolic syndrome status after initiation of antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2015;68(1):73-80.
Kelesidis T, Moser C, Stein JH, et al. "Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s." J. Infect. Dis.. 2016.
Dirajlal-Fargo S, Moser C, Brown TT, et al. "Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s." Open Forum Infect Dis. 2016;3(3):ofw174.
Kelesidis T, Tran TTien T, Stein JH, et al. "Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s." Clin. Infect. Dis.. 2015;61(4):651-60.
Fiscus SA, Cu-Uvin S, Eshete ATilahun, et al. "Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy." Clin. Infect. Dis.. 2013;57(2):290-7.
McComsey GA, Daar ES, O'Riordan MA, et al. "Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202." J. Infect. Dis.. 2013;207(4):604-11.
Brown TT, Moser C, Currier JS, et al. "Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir." J. Infect. Dis.. 2015;212(8):1241-9.
Bhagwat P, Ofotokun I, McComsey GA, et al. "Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes." Antivir. Ther. (Lond.). 2017;22(7):577-586.
Havers FP, Detrick B, Cardoso SW, et al. "Change in vitamin d levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings." PLoS ONE. 2014;9(4):e95164.
Shikuma CM, Ribaudo HJ, Zheng Y, et al. "Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals." AIDS Res. Hum. Retroviruses. 2011;27(5):461-8.
Hughes MD, Williams PL. "Challenges in using observational studies to evaluate adverse effects of treatment." N. Engl. J. Med.. 2007;356(17):1705-7.
Taiwo B, Hunt PW, Gandhi RT, et al. "CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2013;63(1):101-4.
Judge CJ, Kostadinova L, Sherman KE, et al. "CD56NK IL-7Rα expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections." J. Leukoc. Biol.. 2017;102(1):171-184.
Vahey MT, Wang Z, Su Z, et al. "CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway." AIDS Res. Hum. Retroviruses. 2008;24(8):1047-66.
Tassiopoulos K, Landay A, Collier AC, et al. "CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies." J. Infect. Dis.. 2012;205(11):1730-8.
Judge CJ, Sandberg JK, Funderburg NT, et al. "CD14brightCD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy." J. Acquir. Immune Defic. Syndr.. 2016.
Henrich TJ, Hanhauser E, Harrison LJ, et al. "CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy." J. Infect. Dis.. 2016;213(5):766-70.
Shaffer D, Hughes MD, Sawe F, et al. "Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE)." J. Acquir. Immune Defic. Syndr.. 2014;66(2):155-63.

B

Dumond JB, Rigdon J, Mollan K, et al. "Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results." J. Acquir. Immune Defic. Syndr.. 2015;70(5):510-4.
Treasure GC, Aga E, Bosch RJ, et al. "Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials." J. Acquir. Immune Defic. Syndr.. 2016;72(3):310-3.
Macatangay BJ, Yang M, Sun X, et al. "Brief Report: Changes in Levels of Inflammation After Antiretroviral Treatment During Early HIV Infection in AIDS Clinical Trials Group Study A5217." J. Acquir. Immune Defic. Syndr.. 2017;75(1):137-141.
Gupta SK, Yeh E, Kitch DW, et al. "Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s." J. Antimicrob. Chemother.. 2017;72(7):2042-2048.
Huang JS, Hughes MD, Riddler SA, Haubrich RH. "Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142." HIV Clin Trials. 2013;14(5):224-34.
McComsey GA, Kitch D, Daar ES, et al. "Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG." J. Infect. Dis.. 2011;203(12):1791-801.
Palermo B, Bosch RJ, Bennett K, Jacobson JM. "Body mass index and CD4+ T-lymphocyte recovery in HIV-infected men with viral suppression on antiretroviral therapy." HIV Clin Trials. 2011;12(4):222-7.
Brown TT, Chen Y, Currier JS, et al. "Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals." J. Acquir. Immune Defic. Syndr.. 2013;63(3):323-30.

Pages